Clinical trials: Controlled Diabetes
Coronary Artery Disease, Type II Diabetes Mellitus
Innovative Strategies For Risk Reduction Following CABG
Background: Treatment targets for cardiac risk factor reduction are not being met. Therefore, there is a need for new strategies to assist patients in meeting these goals.
- Trial name
- NCT00462436
- Testing
- Consumption of Dietary Portfolio
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Unity Health Toronto
Type 2 Diabetes Mellitus
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and…
- Trial name
- NCT02564211
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Type 2 Diabetes
A Community Health Worker/Pharmacist Team to Improve Blood Sugars in Diabetes Care Using Continuous Glucose Monitoring
Continuous glucose monitoring (CGM) can help improve blood sugar management in type 2 diabetes. A sequential, multiple assignment, randomized trial will evaluate clinical pharmacists, community health workers, and telehealth in…
- Trial name
- TEAM-CGM (NCT05911256)
- Testing
- Pharmacist Only, Continuous Glucose Monitor (CGM), Community Health Worker (CHW)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- University of Massachusetts, Worcester
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus
Computer-Assisted Cancer Risk Behavior Counseling
To test whether or not giving patients information before their doctor visits changes the care they receive and what type of information is best to give before the doctor visit.
- Conditions
- Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- NCT00242645
- Testing
- Health Information, Preventive Services, Computer tailored information
- Volunteers
- 200 people
- Sponsor
- Thomas Jefferson University
Myoma
Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy
In this study, the investigators will investigate the effectiveness of a topical tranexamic acid plus perivascular vasopressin compared with perivascular vasopressin alone for the reduction of blood loss at the time of myomectomy
- Trial name
- NCT03880045
- Testing
- Topical TA, vasopressin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Aswan University Hospital
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Type 2 Diabetes
Digital Diabetes Self Management Education and Support for Patients With Type 2 Diabetes
The purpose of this study is to test the effect of using a digital diabetes self management education and support system compared with standard care for patients with type 2 diabetes in primary health care.
- Trial name
- NCT05026528
- Testing
- Digital diabetes self management education and support system
- Where
- 15 sites in Sweden
- Volunteers
- 138 people
- Sponsor
- Region Jönköping County
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
- Trial name
- NCT00849056
- Testing
- albiglutide
- Where
- 331 sites in United States, India and 4 more
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes, Cardiovascular Disease
Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes
To determine if tree nuts (Almonds, Hazelnuts, Pistachios, Peanuts, Macadamia nuts, Pecans, Walnuts and Cashews) improve glycemic control in type 2 diabetes, as assessed by HbA1c and serum fructosamine, and to assess whether…
- Conditions
- Type 2 Diabetes, Cardiovascular Disease, Diet Therapy
- Trial name
- NCT00410722
- Testing
- Whole wheat and bran muffin, Mixed tree nuts
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University of Toronto
Diabetic Foot Ulcer
A Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC).
- Trial name
- NCT05193929
- Testing
- OptiPulse™, Standard of Care offloading device
- Where
- 19 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Compedica Inc
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Type 1 Diabetes
Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM
This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with…
- Trial name
- NCT06496412
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
Type1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
- Trial name
- iDCL (NCT02985866)
- Testing
- Artificial Pancreas, Sensor Augmented Therapy
- Where
- 7 sites in United States
- Volunteers
- 127 people
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus (T2DM)
Effects of a Multimodal Exercise Program on Physical Performance and Muscle Function in Middle-aged Patients With T2DM
Background Middle-aged adults with type 2 diabetes mellitus (T2DM), especially in Asian populations, are at increased risk of sarcopenia, reduced muscle function, and decline in physical performance.
- Trial name
- NCT07255222
- Testing
- A Multimodal Exercise Intervention
- Where
- Taiwan
- Volunteers
- 66 people
- Sponsor
- Chung Shan Medical University
Type 2 Diabetes Mellitus
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT01044537
- Testing
- PF-04937319
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Peripheral Arterial Disease, Hypercholesterolemia
Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease
The purpose of this study was to evaluate whether an intensified multifactorial intervention program about cardiovascular risk factors in subjects with peripheral arterial disease (with and without diabetes mellitus), can improve…
- Conditions
- Peripheral Arterial Disease, Hypercholesterolemia, Hypertension, Diabetes Mellitus
- Trial name
- NCT00144937
- Testing
- Stepwise therapy for dyslipidemia, hypertension and diabetes, Dietary recommendations, Increase in physical activity
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Hospital de Sabadell
Diabetes
Inulin Supplementation in Patients With Type 1 Diabetes
The aim of this study is to compare the glycemic and metabolic control of type 1 diabetic patients in replacement therapy with insulin, comparing those treated with a supplementation of prebiotics (inulin) and those treated with…
- Trial name
- NCT05795972
- Testing
- inulin, standard therapy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02846857
- Testing
- 15-week intervention with sensor-augmented pump, 15-week intervention with single-hormone closed-loop, 15-week intervention with dual-hormone closed-loop
- Sponsor
- Institut de Recherches Cliniques de Montreal
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.